Table 4. Assay performance compared with RT-qPCR delineated by reported clinical presentation.

	Abbott SARS-CoV2 Architect Assay		Abbott SARS-CoV2 Alinity Assay
Clinical presentation	0–14 days (n = 120)	>14 days (n = 230)	0–14 days (n = 108)	>14 days (n = 192)
Asymptomatic	41.6%	41.6%	36.4%	45.5%
Mild	33.3%	57.1%	33.3%	47.1%
Moderate	47.2%	81.2%	39.4%	73.3%
Severe	74.6%	90%	72.7%	83.3%